子宫内膜增生病变进展的相关性研究
Correlation Study of the Malignant Progression of Endometrial Proliferative Lesions
DOI: 10.12677/ACM.2024.142547, PDF,   
作者: 张蜀苏, 何 艳*：新疆医科大学第一附属医院妇一科，新疆 乌鲁木齐
关键词: 子宫内膜增生；分类演变；危险因素；治疗；Endometrial Hyperplasia； Classification of Evolution； Risk Factors； Treatment
摘要: 子宫内膜增生是非生理性的内膜腺体增生病变，病情进展过程中，非典型增生或子宫上皮内瘤变被称作子宫内膜癌的癌前病变，目前国内外尚无统一的诊疗规范。本文综述了关于子宫内膜增生的分类演变、危险因素和管理治疗的证据基础。据此研究为子宫内膜增生患者恶性病变进展提供警示条件及预防措施，为达到规范诊断及治疗子宫内膜增生提供帮助。
Abstract: Endometrial hyperplasia is a non-physiological endometrial gland hyperplasia lesion. During the progression of the disease, atypical hyperplasia or uterine intraepithelial neoplasia is known as a precancerous lesion of endometrial cancer. At present, there is no unified diagnosis and treatment standard at home and abroad. This review summarizes the evidence based on the evolution of the classification, risk factors, and management of the treatment of endometrial hyperplasia. Accord-ingly, this study provides warning conditions and preventive measures for the progression of ma-lignant lesions in patients with endometrial hyperplasia, and provides help for the standardized diagnosis and treatment of endometrial hyperplasia.
文章引用：张蜀苏, 何艳. 子宫内膜增生病变进展的相关性研究[J]. 临床医学进展, 2024, 14(2): 3930-3936. https://doi.org/10.12677/ACM.2024.142547

参考文献

[1] Morice, P., Leary, A., Creutzberg, C. and Abu-Rustum, N.D.E. (2016) Endometrial Cancer. The Lancet, 387, 1094-1108. [Google Scholar] [CrossRef] 
[2] Doherty, M.T., Sanni, O.B., Coleman, H.G., et al. (2020) Concurrent and Future Risk of Endometrial Cancer in Women with Endometrial Hyperplasia: A Systematic Review and Meta-Analysis. PLOS ONE, 15, e0232231. [Google Scholar] [CrossRef] [PubMed]
[3] Sanderson, P.A., Critchley, H.O.D., Williams, A.R.W., Arends, M.J. and Saunders, P.T.K. (2017) New Concepts for an Old Problem: The Diagnosis of Endometrial Hyperplasia. Human Reproduction Update, 23, 232-254. [Google Scholar] [CrossRef] [PubMed]
[4] World Health Organization (2020) WHO Classification of Tumours. 5th Edition, Volume 4: Female Genital Tumours. WHO, Geneva.
[5] Kurman, R., Careangiu, M., Herrington, C., et al. (2014) World Health Organisation Classification of Tumors of Female Reproductive Organs. 4th Edition, International Agency for Research on Cancer (LARC) Press, Lyon.
[6] 全国卫生产业企业管理协会妇幼健康产业分会生殖内分泌学组. 中国子宫内膜增生诊疗共识[J]. 生殖医学杂志, 2017, 26(10): 957-960.
[7] Committee on Gynecologic Practice Society of Gynecologic Oncology (2015) Committee Opinion No. 631 Endometrial Intraepithelial Neoplasia. Obstetrics & Gynecology, 125, 1272-1278. [Google Scholar] [CrossRef] 
[8] Ordi, J., Bergeron, C., Hardisson, D., McCluggage, W.G., Hollema, H., Felix, A., et al. (2014) Reproducibility of Current Classifications of Endometrial Endometrioid Glandular Proliferations: Further Evidence Supporting a Simplified Classification. Histopathology, 64, 284-292. [Google Scholar] [CrossRef] [PubMed]
[9] Zeleniuch-Jacquotte, A., Akhmedkhanov, A., Kato, I., Koenig, K.L., Shore, R.E., Kim, M.Y., Levitz, M., Mittal, K.R., Raju, U., Banerjee, S, et al. (2001) Postmenopausal Endogenous Oestrogens and Risk of Endometrial Cancer: Results of A Prospective Study. British Journal of Cancer, 84, 975-981. [Google Scholar] [CrossRef] [PubMed]
[10] Nees, L.K., Heublein, S., Steinmacher, S., Juhasz-Böss, I., Brucker, S., Tempfer, C.B. and Wallwiener, M. (2022) Endometrial Hyperplasia as a Risk Factor of Endometrial Cancer. Archives of Gynecology and Obstetrics, 306, 407-421. [Google Scholar] [CrossRef] [PubMed]
[11] Wise, M.R., Gill, P., Lensen, S., Thompson, J.M. and Farquhar, C.M. (2016) Body Mass Index Trumps Age in Decision for Endometrial Biopsy: Cohort Study of Symptomatic Premenopausal Women. American Journal of Obstetrics and Gynecology, 215, 598E591-598E598. [Google Scholar] [CrossRef] [PubMed]
[12] Ring, K.L., Mills, A.M. and Modesitt, S.C. (2022) Endometrial Hyperplasia. Obstetrics & Gynecology, 140, 1061-1075. [Google Scholar] [CrossRef] 
[13] Dumesic, D.A. and Lobo, R.A. (2013) Cancer Risk and PCOS. Steroids, 78, 782-785. [Google Scholar] [CrossRef] [PubMed]
[14] Shan, W., Ning, C., Luo, X., Zhou, Q., Gu, C., Zhang, Z., et al. (2014) Hyperinsulinemia Is Associated with Endometrial Hyperplasia and Disordered Proliferative Endometrium: A Prospective Cross-Sectional Study. Gynecologic Oncology, 132, 606-610. [Google Scholar] [CrossRef] [PubMed]
[15] Campagnoli, C., Abba, C., Ambroggio, S., Brucato, T. and Pasanisi, P. (2013) Life-Style and Metformin for the Prevention of Endometrial Pathology in Postmenopausal Women. Gynecological Endocrinology, 29, 119-124. [Google Scholar] [CrossRef] [PubMed]
[16] Bergman, L., Beelen, M.L., Gallee, M.P., Hollema, H., Benraadt, J. and Van Leeuwen, F.E. (2000) Risk and Prognosis of Endometrial Cancer after Tamoxifen for Breast Cancer. The Lancet (London, England), 356, 881-887. [Google Scholar] [CrossRef] 
[17] Lancaster, J.M., Powell, C.B., Chen, L.M. and Richardson, D.L. (2015) Committee SGOCP: Society of Gynecologic Oncology Statement on Risk Assessment for Inherited Gyne-cologic Cancer Predispositions. Gynecologic Oncology, 136, 3-7. [Google Scholar] [CrossRef] [PubMed]
[18] Ryan, N.A.J., McMahon, R., Tobi, S., Snowsill, T., Esquibel, S., Wallace, A.J., Bunstone, S., Bowers, N., Mosneag, I.E., Kitson, S.J., et al. (2020) The Proportion of Endometrial Tu-mours Associated with Lynch Syndrome (PETALS): A Prospective Cross-Sectional Study. PLOS Medicine, 17, e1003263. [Google Scholar] [CrossRef] [PubMed]
[19] Ledermann, J., Marth, C., Nout, R., Querleu, D., Mirza, M.R., et al. (2016) ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-Up. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO, 27, 16-41.
[20] Manchanda, R., Saridogan, E., Abdelraheim, A., Johnson, M., Rosenthal, A.N., Benjamin, E., Brunell, C., Side, L., Gessler, S., Jacobs, I., et al. (2012) Annual Outpatient Hysteroscopy and Endometrial Sampling (OHES) in HNPCC/ Lynch Syndrome (LS). Archives of Gynecology and Obstetrics, 286, 1555-1562. [Google Scholar] [CrossRef] [PubMed]
[21] Auclair, M.H., Yong, P.J., Salvador, S., Thurston, J., Colgan, T.T.J. and Sebastianelli, A. (2019) Guideline No. 390- Classification and Management of Endometrial Hyperplasia. Journal of Obstetrics and Gynaecology Canada, 41, 1789- 1800. [Google Scholar] [CrossRef] [PubMed]
[22] Moore, E. and Shafi, M. (2013) Endometrial Hyperplasia. Ob-stetrics, Gynaecology and Reproductive Medicine, 23, 88-93. [Google Scholar] [CrossRef] 
[23] Concin, N., Matias-Guiu, X., Vergote, I., Cibula, D., Mirza, M.R., Marnitz, S., Ledermann, J., Bosse, T., Chargari, C., Fagotti, A., et al. (2021) ESGO/ESTRO/ESP Guidelines for the Management of Patients with 25 Endometrial Carcinoma. International Journal of Gynecological Cancer, 31, 12-39. [Google Scholar] [CrossRef] [PubMed]
[24] Uccella, S., Zorzato, P.C., Dababou, S., Bosco, M., Torella, M., Braga, A., Frigerio, M., Gardella, B., Cianci, S., Laganà, A.S., Franchi, M.P. and Garzon, S. (2022) Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women. Medicina (Kaunas), 58, Article No. 1256. [Google Scholar] [CrossRef] [PubMed]
[25] Obermair, A., Baxter, E., Brennan, D.J., McAlpine, J.N., Muellerer, J.J., Amant, F., Van Gent, M.D.J.M., Coleman, R.L., Westin, S.N., Yates, M.S., et al. (2020) Fertility-Sparing Treatment in Early Endometrial Cancer: Current State and Future Strategies. Obstetrics & Gynecology Science, 63, 417-431. [Google Scholar] [CrossRef] [PubMed]
[26] Stewart, K., Campbell, S., Frumovitz, M., Ramirez, P.T. and McKenzie, L.J. (2021) Fertility Considerations Prior to Conservative Management of Gynecologic Cancers. International Journal of Gynecological Cancer, 31, 339-344. [Google Scholar] [CrossRef] [PubMed]
[27] Moradan, S., Nikkhah, N. and Mirmohammadkhanai, M. (2017) Comparing the Administration of Letrozole and Megestrol Acetate in the Treatment of Women with Simple Endometrial Hyperplasia without Atypia: A Randomized Clinical Trial. Advances in Therapy, 34, 1211-1220. [Google Scholar] [CrossRef] [PubMed]
[28] Park, J.Y., Lee, S.H., Seong, S.J., et al. (2013) Progestin Re-Treatment in Patients with Recurrent Endometrial Adenocarcinoma after Successful Fertility-Sparing Management Using Progestin. Gynecologic Oncology, 129, 7-11. [Google Scholar] [CrossRef] [PubMed]
[29] Contreras, N.A., Sabadell, J., Verdaguer, P., Julià, C. and Fernández-Montolí, M.E. (2022) Fertility-Sparing Approaches in Atypical Endometrial Hyperplasia and Endometrial Cancer Patients: Current Evidence and Future Directions. International Journal of Molecular Sciences, 23, Article No. 2531. [Google Scholar] [CrossRef] [PubMed]

为你推荐